Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try

BACKGROUND: For gravely ill patients who have no treatment options and who are ineligible for clinical trials, the US Food and Drug Administration (FDA) established the Expanded Access Program (EAP). Motivated by efforts to weaken FDA regulation and sold as providing greater access to experimental d...

Descripción completa

Detalles Bibliográficos
Autores principales: Manley, Haley, Sisk, Bryan A, Master, Zubin, Scott, Christopher Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596169/
https://www.ncbi.nlm.nih.gov/pubmed/36419857
http://dx.doi.org/10.1093/jlb/lsac031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596169/
https://www.ncbi.nlm.nih.gov/pubmed/36419857
http://dx.doi.org/10.1093/jlb/lsac031

Ejemplares similares